These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9582521)

  • 1. No p16INK4A/CDKN2/MTS1 mutations independent of p53 status in soft tissue sarcomas.
    Meye A; Würl P; Hinze R; Berger D; Bache M; Schmidt H; Rath FW; Taubert H
    J Pathol; 1998 Jan; 184(1):14-7. PubMed ID: 9582521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma.
    Yao J; Pollock RE; Lang A; Tan M; Pisters PW; Goodrich D; El-Naggar A; Yu D
    Clin Cancer Res; 1998 Apr; 4(4):1065-70. PubMed ID: 9563903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant expression of cell-cycle regulatory proteins in human mesenchymal neoplasia.
    Creager AJ; Cohen JA; Geradts J
    Cancer Detect Prev; 2001; 25(2):123-31. PubMed ID: 11341347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
    Fujishita T; Mizushima Y; Kashii T; Kobayashi M
    Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis.
    Kawaguchi K; Oda Y; Saito T; Yamamoto H; Tamiya S; Takahira T; Miyajima K; Iwamoto Y; Tsuneyoshi M
    J Pathol; 2003 Nov; 201(3):487-95. PubMed ID: 14595762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
    Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.
    Sartor M; Steingrimsdottir H; Elamin F; Gäken J; Warnakulasuriya S; Partridge M; Thakker N; Johnson NW; Tavassoli M
    Br J Cancer; 1999 Apr; 80(1-2):79-86. PubMed ID: 10389982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 gene mutations and p53 protein expression in human soft tissue sarcomas.
    Yoo J; Lee HK; Kang CS; Park WS; Lee JY; Shim SI
    Arch Pathol Lab Med; 1997 Apr; 121(4):395-9. PubMed ID: 9140310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p53 gene in soft tissue sarcomas: prognostic value of DNA sequencing versus immunohistochemistry.
    Taubert H; Würl P; Bache M; Meye A; Berger D; Holzhausen HJ; Hinze R; Schmidt H; Rath FW
    Anticancer Res; 1998; 18(1A):183-7. PubMed ID: 9568075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland.
    Weber A; Langhanki L; Schütz A; Wittekind C; Bootz F; Tannapfel A
    J Pathol; 2002 Nov; 198(3):326-34. PubMed ID: 12375265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
    Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
    Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of p16INK4A gene promoter in male germ-cell tumors: identification of a new point mutation.
    Fombonne J; Devouassoux-Shisheboran M; Bouvier R; Droz JP; Benahmed M; Krantic S
    Cancer Detect Prev; 2005; 29(1):1-7. PubMed ID: 15734211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.
    Oda Y; Yamamoto H; Takahira T; Kobayashi C; Kawaguchi K; Tateishi N; Nozuka Y; Tamiya S; Tanaka K; Matsuda S; Yokoyama R; Iwamoto Y; Tsuneyoshi M
    J Pathol; 2005 Dec; 207(4):410-21. PubMed ID: 16177957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
    Elisei R; Shiohara M; Koeffler HP; Fagin JA
    Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus.
    Lee JY; Dong SM; Shin MS; Kim SY; Lee SH; Kang SJ; Lee JD; Kim CS; Kim SH; Yoo NJ
    Biochem Biophys Res Commun; 1997 Aug; 237(3):667-72. PubMed ID: 9299424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation of the p53 gene in postradiation sarcoma.
    Nakanishi H; Tomita Y; Myoui A; Yoshikawa H; Sakai K; Kato Y; Ochi T; Aozasa K
    Lab Invest; 1998 Jun; 78(6):727-33. PubMed ID: 9645763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma.
    Hirabayashi H; Fujii Y; Sakaguchi M; Tanaka H; Yoon HE; Komoto Y; Inoue M; Miyoshi S; Matsuda H
    Int J Cancer; 1997 Nov; 73(5):639-44. PubMed ID: 9398039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of p53 exon 4 mutations in soft tissue sarcoma.
    Das P; Kotilingam D; Korchin B; Liu J; Yu D; Lazar AJ; Pollock RE; Lev D
    Cancer; 2007 Jun; 109(11):2323-33. PubMed ID: 17429838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular control of the cell cycle in cancer: biological and clinical aspects.
    Møller MB
    Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.
    Spanakis NE; Gorgoulis V; Mariatos G; Zacharatos P; Kotsinas A; Garinis G; Trigidou R; Karameris A; Tsimara-Papastamatiou H; Kouloukousa M; Manolis EN; Kittas C
    Anticancer Res; 1999; 19(3A):1893-9. PubMed ID: 10470133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.